Loading...
Market
Will J&J's Rybrevant receive another FDA approval for a different indication by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA approval announcements and J&J press releases
Story
FDA Approves J&J's Rybrevant for EGFR-Mutated NSCLC, Third New Indication in 2024
Sep 19, 2024, 10:21 PM
The U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with standard care for the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). This approval marks the first targeted regimen to significantly reduce the risk of disease progression by more than half in the second-line setting and is the third new indication for Johnson & Johnson (J&J) in 2024. This development is part of a broader trend of advancements in lung cancer treatment, highlighted at the 2024 IASLC World Conference on Lung Cancer (WCLC24).
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5% to 10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%